{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.269","value":"-13.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.795","value":"-0.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.803","value":"-4.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.914","value":"-3.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 78"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.530","value":"-1.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.019","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 128"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.452","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 156"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.005","value":"-0.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Change at Day 184"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.586","value":"2.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Change at Day 212"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.660","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Change at Day 240"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.607","value":"-2.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Change at Day 268"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.749","value":"-12.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Change at Day 296"},{"categories":[{"measurements":[{"comment":"Here, 'NA' signifies that SD could not be calculated as only 1 participant was analyzed.","groupId":"OG000","spread":"NA","value":"-10.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Change at Day 324"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"EQ-5D-5L was a 5-item questionnaire consisted of 2 components: a health state profile/a single utility index value and an optional VAS. EQ-5D health state profile/a single utility index value had 5 dimensions including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 response levels: 1 =no problems, 2 =slight problems, 3 =moderate problems, 4 =severe problems and 5 =extreme problems. The scores for the 5 dimensions were used to compute a single utility score ranging from 0 to 1 representing the general health status of the individual. Higher score indicated better health status. EQ-5D VAS was used to record participant's rating for his/her \"health today\" and ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG000","title":"Phase 2 (US Population)"}],"paramType":"MEAN","populationDescription":"mITT analysis Set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Days 7, 28, 56, 78, 100, 128, 156, 184, 212, 240, 268, 296 and 324","title":"Phase 2 (Japan Population): Change From Baseline in EuroQol Five Dimension Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Score at Days 7, 28, 56, 78, 100, 128, 156, 184, 212, 240, 268, 296 and 324","type":"SECONDARY","unitOfMeasure":"Score on a scale"}